Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Posterior Reversible Encephalopathy Syndrome (PRES) With Immune System Activation, VEGF Up-Regulation, and Cerebral Amyloid Angiopathy

Posterior Reversible Encephalopathy Syndrome (PRES) With Immune System Activation, VEGF... CASE REPORT Posterior Reversible Encephalopathy Syndrome (PRES) With Immune System Activation, VEGF Up-Regulation, and Cerebral Amyloid Angiopathy Julia Kofler, MD,* Walter S. Bartynski, MD,Þ Thomas Q. Reynolds, DO,þ Frank S. Lieberman, MD,þ Geoffrey H. Murdoch, MD, PhD,* and Ronald L. Hamilton, MD* chemotherapy regimens (rituximab, cyclophosphamide, doxo- Abstract: The case of a 75-year-old man with a history of lymphoma, rubicin, vincristine, and prednisone; and fludaribine, cyclo- recent upper respiratory tract infection, and a protracted course of en- phosphamide, and rituximab). He presented 12 weeks after the cephalopathy is presented. Radiologically, findings were consistent with fifth fludaribine, cyclophosphamide, and rituximab cycle with posterior reversible encephalopathy syndrome. A brain biopsy revealed headache, confusion, cough, myalgias, arthralgias, nausea, and evidence of endothelial activation, T-cell trafficking, and vascular en- fever. Recent positron emission tomographyYcomputed tomog- dothelial growth factor expression, suggesting that systemic immune raphy (CT) demonstrated positive tumor response to therapy system activation may be involved with triggering posterior reversible with substantial nodal regression, but further chemotherapy was encephalopathy syndrome. In addition, underlying cerebral amyloid held because of myelosuppression. Antibiotic and antiviral angiopathy may have contributed to the initial nonclassical edema dis- treatment was initiated. Results of chest radiograph, blood and tribution by http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Computer Assisted Tomography Wolters Kluwer Health

Posterior Reversible Encephalopathy Syndrome (PRES) With Immune System Activation, VEGF Up-Regulation, and Cerebral Amyloid Angiopathy

Download PDF
4 pages

Loading next page...
 
/lp/wolters-kluwer-health/posterior-reversible-encephalopathy-syndrome-pres-with-immune-system-QhIqCNi08M

References (20)

ISSN
0363-8715
eISSN
1532-3145
DOI
10.1097/RCT.0b013e3181f31917
pmid
21150450
Publisher site
See Article on Publisher Site

Abstract

CASE REPORT Posterior Reversible Encephalopathy Syndrome (PRES) With Immune System Activation, VEGF Up-Regulation, and Cerebral Amyloid Angiopathy Julia Kofler, MD,* Walter S. Bartynski, MD,Þ Thomas Q. Reynolds, DO,þ Frank S. Lieberman, MD,þ Geoffrey H. Murdoch, MD, PhD,* and Ronald L. Hamilton, MD* chemotherapy regimens (rituximab, cyclophosphamide, doxo- Abstract: The case of a 75-year-old man with a history of lymphoma, rubicin, vincristine, and prednisone; and fludaribine, cyclo- recent upper respiratory tract infection, and a protracted course of en- phosphamide, and rituximab). He presented 12 weeks after the cephalopathy is presented. Radiologically, findings were consistent with fifth fludaribine, cyclophosphamide, and rituximab cycle with posterior reversible encephalopathy syndrome. A brain biopsy revealed headache, confusion, cough, myalgias, arthralgias, nausea, and evidence of endothelial activation, T-cell trafficking, and vascular en- fever. Recent positron emission tomographyYcomputed tomog- dothelial growth factor expression, suggesting that systemic immune raphy (CT) demonstrated positive tumor response to therapy system activation may be involved with triggering posterior reversible with substantial nodal regression, but further chemotherapy was encephalopathy syndrome. In addition, underlying cerebral amyloid held because of myelosuppression. Antibiotic and antiviral angiopathy may have contributed to the initial nonclassical edema dis- treatment was initiated. Results of chest radiograph, blood and tribution by

Journal

Journal of Computer Assisted Tomography – Wolters Kluwer Health

Published: Jan 1, 2011

There are no references for this article.